NEA Management Company’s Mersana Therapeutics MRSN Stock Holding History

NEA Management Company’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-238,381	Closed	-$111M	–	59
2020 Q3	$111M	Sell	238,381 -80,000	-25%	-$40.4M	4.7%	6
2020 Q2	$186M	Sell	318,381 -160,165	-33%	-$54.7M	7.49%	2
2020 Q1	$69.7M	Hold	478,546	–	–	3.64%	11
2019 Q4	$68.6M	Hold	478,546	–	–	3.24%	12
2019 Q3	$18.9M	Buy	478,546 +2,775	+0.6%	+$202K	1.57%	20
2019 Q2	$48.2M	Hold	475,771	–	–	3.37%	11
2019 Q1	$62.6M	Buy	475,771 +150,000	+46%	+$18.9M	3.25%	11
2018 Q4	$33.2M	Hold	325,771	–	–	1.32%	14
2018 Q3	$81.4M	Hold	325,771	–	–	3.51%	10
2018 Q2	$145M	Hold	325,771	–	–	6.81%	5
2018 Q1	$128M	Hold	325,771	–	–	5.71%	5
2017 Q4	$134M	Hold	325,771	–	–	5.54%	4
2017 Q3	$141M	Hold	325,771	–	–	4.93%	2
2017 Q2	$114M	Buy	+325,771	New	+$113M	4.14%	2

Other funds holding MRSN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

NEA Management Company's MRSN Position: Q4 2020 in Review

NEA Management Company sold out of Mersana Therapeutics (MRSN) in Q4 2020, closing a stake of 238,381 shares — an estimated $111M sold.

NEA Management Company first reported a position in MRSN in Q2 2017 and held it in 14 quarters. The position peaked at $186M in Q2 2020. 151 funds tracked by Wall St. Rank hold MRSN as of Q4 2020.

NEA Management Company reported no remaining Mersana Therapeutics position as of Q4 2020 after selling out during the quarter.
NEA Management Company sold 238,381 Mersana Therapeutics shares in Q4 2020, an estimated $111M.
NEA Management Company first reported a position in Mersana Therapeutics in Q2 2017 and held it in 14 quarters.
NEA Management Company's Mersana Therapeutics position peaked at $186M in Q2 2020.
151 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2020.

Based on NEA Management Company's 13F filing for Q4 2020, filed 16 Feb 2021.